MedTrace Logo

Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome

NCT05976204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 501

Last updated 2023-08-08

No results posted yet for this study

Summary

Tetralogy of Fallot (ToF) were cyanotic congenital heart disease with chronic hypoxia which increases the risk of exacerbated inflammatory response in ToF primary repair. Various studies have recently shown inflammatory biomarkers to predict morbidity and mortality in hypoxemic patients, but they are not readily available and expensive.This study aims to compare the prognostic value of neutrophil-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and thrombocyte-lymphocyte ratio (TLR) in predicting ToF primary repair outcomes. This was a retrospective observational study on ToF primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. Preoperative NLR, ALC, and TLR were derived from blood test obtained \<14 days before surgery. The primary endpoints were redo surgery, 30-day mortality, and complications. The secondary endpoints were hospital length of stay (HLOS) and postoperative LOS.

Conditions

  • Congenital Heart Disease
  • Tetralogy of Fallot
  • Neutrophil-lymphocyte Ratio
  • Absolute Lymphocyte Count
  • Thrombocyte-lymphocyte Ratio
  • Outcome
  • TOF

Interventions

PROCEDURE

ToF primary repair

ToF primary repair for patients with ToF

Sponsors & Collaborators

  • National Cardiovascular Center Harapan Kita Hospital Indonesia

    lead OTHER

Principal Investigators

  • Sisca N Siagian, MD · National CCHK

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05976204 on ClinicalTrials.gov